Rybelsus®

Semaglutide

Rybelsus comprimidos (semaglutide) é um medicamento de prescrição utilizado em adultos com diabetes mellitus tipo 2 para diminuir os níveis de açúcar no sangue. O Rybelsus pode ser prescrito quando outros medicamentos para a diabetes foram experimentados sem sucesso e devem ser utilizados em conjunto com dieta e Exercício. Os comprimidos de Rybelsus actuam para reduzir os níveis de açúcar no sangue (glucose), aumentando a quantidade de insulina libertada e diminuindo a secreção de glucagão. Este medicamento também pode retardar o esvaziamento gástrico após a ingestão.
more
Embalagem Por comprimido Preço Poupança Encomenda
90 tablet
Free AirMail shipping Hot
€ 13.93
€ 1254.10€ 13.93
€ 167.13
60 tablet
Free AirMail shipping Hot
€ 14.86
€ 891.79€ 14.86
€ 55.69
30 tablet
Free AirMail shipping Hot
€ 15.79
€ 473.74€ 15.79
Embalagem Por comprimido Preço Poupança Encomenda
90 tablet
Free AirMail shipping Hot
€ 16.72
€ 1504.93€ 16.72
€ 83.52
60 tablet
Free AirMail shipping Hot
€ 17.19
€ 1031.14€ 17.19
€ 27.82
30 tablet
Free AirMail shipping Hot
€ 17.65
€ 529.48€ 17.65
Embalagem Por comprimido Preço Poupança Encomenda
90 tablet
Free AirMail shipping Hot
€ 19.97
€ 1797.57€ 19.97
€ 83.52
60 tablet
Free AirMail shipping Hot
€ 20.44
€ 1226.23€ 20.44
€ 27.82
30 tablet
Free AirMail shipping Hot
€ 20.90
€ 627.03€ 20.90
Rybelsus

Marca(s)

Fabricante

  • Novo Nordisc India Pvt. Ltd

Diseases

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.